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ABSTRACT
Background In 2010 the WHO issued a revision of the
guidelines on antiretroviral therapy (ART) for HIV
infection in adults and adolescents. The
recommendations included earlier diagnosis and
treatment of HIV in the interest of a longer and healthier
life. The current analysis explores the impact on the
estimates of treatment needs of the new criteria for
initiating ART compared with the previous guidelines.
Methods The analyses are based on the national models
of HIV estimates for the years 1990e2009. These
models produce time series estimates of ART treatment
need and HIV-related mortality. The ART need estimates
based on ART eligibility criteria promoted by the 2010
WHO guidelines were compared with the need
estimates based on the 2006 WHO guidelines.
Results Withthe2010eligibilitycriteria,theproportionof
people living with HIV currently in need of ART is
estimated to increase from 34% to 49%. Globally, the
need increases from 11.4 million (10.2e12.5 million) to
16.2 million (14.8e17.1 million). Regional differences
include 7.4 million (6.4e8.4 million) to 10.6 million
(9.7e11.5 million) in sub-Saharan Africa, 1.6 million
(1.3e1.7 million) to 2.4 million (2.1e2.5 million) in Asia
and 710000 (610000e780000) to 950000
(810000e1.0million)inLatinAmericaandtheCaribbean.
Conclusions When adopting the new
recommendations, countries have to adapt their planning
process in order to accelerate access to life saving drugs
to those in need. These recommendations have
a signiﬁcant impact on resource needs. In addition to
improving and prolonging the lives of the infected
individuals, it will have the expected beneﬁt of reducing
HIV transmission and the future HIV/AIDS burden.
INTRODUCTION
The most recent UNAIDS/WHO global epidemic
update estimates that, in 2009, around 33.3 million
people (31.4e35.3 million) were living with HIV
globally.
1 Of these, 10 million (9e11 million)
people in low- and middle-income countries are
estimated to be in need of antiretroviral therapy
(ART) in accordance with the 2006 WHO guide-
lines. According to the latest 2009 reported data on
the health response towards universal access, 5.25
million people in low- and middle-income coun-
tries, 52% (47e58%) of those in need of ART based
on the previous guidelines, were receiving treat-
ment.
2 An estimated 4.5 million life-years have
been gained in low- and middle-income countries
since 1995.
3
Since the last publication of the WHO guideline
Antiretroviral Therapy for HIV Infection in Adults and
Adolescents in 2006, new and compelling evidence
has become available concerning the earlier start of
ART.
4 There is increasing evidence that rates of
death, morbidity and HIV and tuberculosis (TB)
transmission are all reduced by starting ARTearlier.
This prolongs and improves quality of life. The
WHO issued a revision to this guideline in July
2010.
5 One of the main recommendations of the
updated guidelines is to start ART in all patients
with HIV who have a CD4 count of #350 cells/
mm
3 irrespective of clinical symptoms.
These revisions are based on a thorough review of
the available evidence, including two randomised
controlled trials and several observational studies
conducted largely in developed countries. The
evidence suggests that earlier initiation of ART
decreases non-AIDS events as well as improving
survival.
6e9 Most developed countries and indeed
some countries in Africa are moving to earlier
initiation of ART.
61 01 1In the interest of avoiding
non-AIDS mortality and of preventing HIVand TB
transmission, even higher thresholds for ART
initiation are now gaining consideration.
81 2
In this paper we present two sets of analyses
related to adult eligibility for ART: ﬁrst we estimate
thenumberofadults(age$15 years)inneedofART
from 1990 through 2009 based on the 2006 WHO
guidelines and, second, we estimate the number of
adults (age $15 years) eligible for ART based on the
revised 2010 WHO guidelines for the same time
period. For allof these analyses we present estimates
for low- and middle-income countries, with
a primary focus on sub-Saharan Africa, and discuss
the implication of these revisions.
METHODS
The national and global HIV estimation process
began with country-speciﬁc estimates of HIV
prevalence collected through biennial regional
workshops involving country teams and analysed
using the Estimates and Projection Package (EPP),
Workbook and Spectrum software whose method-
ology is described elsewhere.
13e16 The software is
freely and publicly available (http://www.unaids.
org/en/KnowledgeCentre/HIVData/Epidemiology/
EPI_software2009.asp). Country-speciﬁc HIV esti-
mates produced by Spectrum are also available
from the AIDS Info UNAIDS website.
17
Brieﬂy, for countries with a generalised epidemic,
EPP ﬁts a simple epidemiological model developed
by the UNAIDS Reference Group on Estimates,
Modelling and Projections to observed HIV
surveillance data using Bayesian melding.
18 For
countries with generalised epidemics, the HIV
prevalence curves are ﬁtted to HIV prevalence data
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Supplementamong women tested in antenatal clinics. The ﬁts are usually
done separately for rural and urban areas. For countries with
a concentrated epidemic, the prevalence of HIV is estimated by
combining the HIV prevalence in speciﬁc high- and low-risk
population groups with an estimate of the size of these groups.
For countries with enough trend data, EPP is used to ﬁt a curve
for the various high- and low-risk populations. For countries
with limited data, the Workbook method is repeated for several
years and then a prevalence trend is derived in EPP. The Work-
book method is a spreadsheet used to estimate the adult prev-
alence of HIV from surveillance data in countries that lack HIV
prevalence data from consistent sites over time. Estimates are
based on prevalence in populations with high-risk behaviours
and populations at low risk, as well as estimates of the size of
populations with high-risk behaviours. For countries where
a national household survey has collected HIV prevalence data,
this information is used as well as the sentinel surveillance data
to inform the estimates of adult prevalence and the male:female
ratios.
Time trends of adult HIV incidence are then transferred to
Spectrum and the data are entered for coverage of all prevention
of mother-to-child transmission (PMTCT) interventions
(notably ARV for prophylaxis, or ART for the mother’s own
health, infant feeding modes and duration), and adult and child
ART for each year. Estimated HIVoutcomes (eg, HIV incidence,
HIV prevalence, HIV-related mortality by age and sex and ART
need for adults and children) are then produced using the AIDS
Impact Model (AIM) module from Spectrum. AIM calculates
the effects of ART based on assumptions on HIV progression
over time about the proportion of those in need receiving ART
and survival on ARTon ﬁrst and second line. ART is assumed to
delay progression to death as long as it is effective. The popu-
lation that is infected with HIV but asymptomatic will progress
to needing ART over time. Patterns of progression from new
infection to eligibility for ARTand from eligibility to AIDS death
in the absence of ART were developed based on data from the
ALPHA network on overall progression from infection to
death,
19 e-ART Linc data on time from infection to different
CD4 count levels
20 and further reﬁned by comparison with
community-based distribution data on CD4.
21
Eligibility for treatment can be deﬁned in Spectrum as either
aC D 4c o u n to f#200 cells/mm
3 or a CD4 count of #350 cells/
mm
3. The assumption regarding time from infection to ART
eligibility is approximately 6 years for a CD4 count of
#350 cells/mm
3 and approximately 8 years for a CD4 count of
#200 cells/mm
3 for a total survival of 11 years based on the
above progression patterns. Once a person progresses to need
for ART, they will subsequently progress to AIDS death if they
do not start on ART. The number of adults in need of ART is
the total of all people already receiving ART, those currently in
need of ART but who have not yet started, and those who will
reach the criteria for ART initiation over the reporting period.
Based on a review of available data from published and grey
literature, survival on ART in the ﬁrst year is assumed to
be 86% and in subsequent years the survival is estimated
at 90%.
20
Spectrum produces a point estimate for each year, but there
may be a considerable amount of uncertainty associated with
each point estimate. Bounds are estimated by cumulating
uncertainty for each step in the calculation for a typical gener-
alised or concentrated epidemic and applying the resulting
bounds to all countries.
13
Spectrum projections from 117 low- and middle-income
countries from sub-Saharan Africa, Latin America and the
Caribbean, Eastern Europe and Asia were used in this study and
all results throughout refer to these countries. A description of
the countries that fall into each region is available from the
UNAIDS AIDS Info site.
17 For each country, two Spectrum
projections were createddone with adult ART eligibility set at
a CD4 count of #200 cells/mm
3 and a second projection with
a CD4 count of #350 cells/mm
3. Estimates of the number of
adults eligible for ART were extracted from Spectrum for each
country and summed by region and globally.
RESULTS
The number of people in low- and middle-income countries
eligible for ART under the revised WHO guidelines is 14.6
million (13.4e15.4 million) compared with the estimated 10.1
million (9.0e11.1 million) people in need under the previous
guidelines (ﬁgure 1). This represents a 45% increase in the
number of people eligible for ART.
Sub-Saharan Africa represents 73% of the ART need burden in
low- and middle-income countries (ﬁgure 2). Under the new
guidelines, 10.6 million (9.7e11.5 million) people were eligible
for ART in 2009 compared with the estimated 7.4 million
(6.4e8.4 million) in need of ART under the earlier guidelines
(44% increase). Asia represents 16% of the burden with the
estimated number of people now eligible for ARTat 2.4 million
(2.1e2.5 million) compared with an estimate of 1.6 million
(1.4e1.7 million) under the previous guidelines (51% increase).
Similarly, in Central and South America with 5% of the ART
burden, the number eligible is estimated at 730000
(600000e810000) compared with the estimated need of 550000
(470000e600000) under the previous guidelines (32% increase).
In Eastern Europe and Central Asia with over 4% of the ART
burden, the number of people eligible for ART is estimated at
570000 (510000e660000) compared with the estimated need
under the previous guidelines of 340000 (280000e410000)
(68% increase). In the Caribbean the number of people estimated
to be eligible for ART is 110000 (95000e110000) compared
with an estimated need of 78000 (65000e91000) under the
previous guidelines (39% increase).
In sub-Saharan Africa the number of people eligible for ART
under the new guidance is highest in South Africa (2.6 million
(2.5e2.8 million)) and in Nigeria (1.4 million (1.2e1.6 million)),
up from the estimated 1.7 million (1.5e2.0 million) and 1.0
million (790000e1.2 million), respectively, based on the 2006
guidelines (ﬁgure 3). In Kenya nearly 750000 (600000e800000)
people are eligible for ART compared with 520000
(430000e600000) under the previous guidelines. In
Mozambique, Tanzania and Zimbabwe, around 650000
(580000e750000) people are eligible for ART under the new
2010 ART guidelines.
For countries that had reached a high level of coverage under
the 2006 WHO guidelines such as Botswana and Zambia, the
proportional increase in the numbers of people eligible for ART
in 2009 is lower than for those countries with lower coverage
rates (table 1). On the other hand, the proportional increase
between the two guidelines is higher for Mozambique with 39%
coverage on ART based on the 2006 guidelines.
DISCUSSION
As expected, increasing the CD4 cell count threshold for the
initiation of ART increases the overall number of people eligible
for ART in low- and middle-income countries to 14.6 million
(13.4e15.4 million). This represents a 45% increase over the last
ART need estimates under the previous guidelines of 10.1
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Supplementmillion (9.0e11.1 million). However, there is an important
variation in the increase by region.
There are three factors that determine the increase in the
number of people eligible for ART: (1) the stage and start of the
epidemic; (2) the number of people already on ARTand the rate of
scale-up of ART programmes; and (3) the survival rate of people
on ARTand the rate at which they switch to second-line therapy.
We use theoretical models to show the impact of changing
criteria for the initiation of ART. In practice this impact may
differ by country as, in general, HIV testing and diagnosis
remain insufﬁcient, limiting the numbers receiving ART irre-
spective of initiation criteria. In order for the scale-up of ART to
reach universal access, the rates of HIV diagnosis must be
increased but this remains a signiﬁcant obstacle for many
countries. The practical impact of guideline changes is therefore
difﬁcult to determine and needs further evaluation.
As was the case with the estimated proportional increase
between the two guidelines in the number of people eligible for
treatment in those countries listed in table 1, similar results can
be seen for the regions. The 2009 estimated ART coverage for
Eastern Europe and Central Asia was reported as 19%.
2 For this
region, the estimated proportional increase in the number of
people eligible for ART according to the two guidelines is 0.68,
compared with a proportional increase in Central and South
America of 0.36 where ART coverage is >50%. Countries and
regions that had managed to increase the number of people in
need on ARTwill be closer to reaching those now eligible with
the new criteria.
Any proposed increase in the threshold for ART initiation
would have a profound impact for many countries. The costs
associated with attempting to provide this degree of coverage
would clearly increase in the short term. However, given that
the vast majority of people in low- and middle-income countries
are on ﬁrst-line ART, our estimations are likely to be accurate.
22
A factor not considered in our estimates is that ﬁrst-line failure
rates may be lower when ART is initiated earlier. If true, this
could defray some of the costs associated with earlier initiation
of ART, but data to support this are not currently available.
Clearly, the costs associated with drug procurement alone would
be signiﬁcant if ART is initiated earlier.
Figure 1 Global number of adults
($15 years) eligible for antiretroviral
therapy (ART) in low- and middle-
income countries in 1990e2009
according to WHO guidelines for 2006
and 2009.
Figure 2 Number of adults ($15 years) eligible for antiretroviral therapy (ART) by region in 1990e2009 according to WHO guidelines for 2006 and
2010.
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SupplementBeyond the costs of medications, non-drug-related costs of
providing ART need to be reduced.
23 They currently outweigh
the cost of the drugs themselves.
24 Additional needs would
include the scale-up of counselling and testing, more laboratory
tests to assess CD4 count and to monitor drug toxicity, the
recruitment and training of healthcare workers, and changes in
the logistics and infrastructure framework to absorb these
patients into the healthcare system.
Since the early 1990s, effective ART has been seen as
a prevention strategy for the transmission of HIV. ART reduces
both sexual and vertical transmission of HIV.
25 26 A recent study
from seven sub-Saharan African countries of couples where one
partner was HIV-positive and the other was not found that,
when the HIV-positive partner was on ART, the HIV trans-
mission rate was 92% lower than among couples where the
person living with HIV did not receive ART.
27 Similarly, it has
been shown that maternal triple-drug ART used through preg-
nancy and breastfeeding reduce vertical transmission to 1% (and
lowers the risk of prematurity, stillbirth and abortion).
28
Treating everyone eligible for ART according to the new guide-
lines could result in a one-third reduction in new infections
globally.
29
In the context of limited resources, more efﬁcient and cost-
effective mechanisms to deliver care and treatment to those on
need needs to be implemented worldwide.
This modelling exercise indicates that initiating ARTearlier in
the course of the disease by increasing the threshold for the
initiation of ART would immediately increase the numbers of
adults eligible for ART. Although this would clearly have an
associated cost and burden on the health system, potential
Figure 3 Number of adults ($15 years) in sub-Saharan Africa eligible for ART by country in 2009 according to WHO guidelines for 2006 and 2010.
Table 1 Difference in the number eligible for antiretroviral therapy (ART) in 2009 in sub-Saharan Africa:
2006 WHO guidelines compared with 2010 WHO guidelines
Country
ART need in 2009
Coverage of
ART based
on 2006
guidelines (%)
Number
of people
on ART
Based
on 2006
guidelines
Based
on 2010
guidelines Difference*
Proportional
increase
between the
two guidelines
Botswana 140000 170000 33000 0.24 103 150000
Cameroon 180000 270000 85000 0.46 41 76000
Central African Republic 51000 74000 23000 0.45 28 14000
Kenya 520000 700000 190000 0.37 65 340000
Lesotho 90000 130000 39000 0.43 68 62000
Malawi 310000 440000 120000 0.39 63 200000
Mozambique 380000 570000 190000 0.51 39 170000
South Africa 1700000 2600000 900000 0.51 56 970000
Swaziland 56000 80000 24000 0.43 85 47000
Uganda 380000 520000 140000 0.36 54 200000
United Republic of Tanzania 450000 660000 210000 0.45 44 200000
Zambia 330000 440000 110000 0.33 85 280000
Zimbabwe 450000 640000 190000 0.43 49 220000
*Due to rounding-off, some values may appear not to be the exact difference.
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Supplementbeneﬁts lie not only in improving the individual’s health but also
in reducing the transmission of HIV and reducing the HIV
burden into the future.
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Key messages
< Changes in the WHO guidelines for starting ART have
increased the number of people eligible for treatment to 49%.
< In low- and middle- income countries, an estimated 14.6
million (13.4e15.4 million) people are eligible for treatment.
< Sub-Saharan Africa represents nearly three-quarters of the
ART treatment burden with an estimated 10.6 million
(9.7e11.5 million) people who are eligible for ART under
the new guidelines.
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